Neuroscience

Articles and news from the latest research reports.

183 notes

MRI Can Screen Patients for Alzheimer’s Disease or Frontotemporal Lobar Degeneration, Using Penn-designed Model
When trying to determine the root cause of a person’s dementia, using an MRI can effectively and non-invasively screen patients for Alzheimer’s disease or Frontotemporal Lobar Degeneration (FTLD), according to a new study by researchers from the Perelman School of Medicine at the University of Pennsylvania. Using an MRI-based algorithm effectively differentiated cases 75 percent of the time, according to the study, published in the December 26th, 2012, issue of Neurology, the medical journal of the American Academy of Neurology. The non-invasive approach reported in this study can track disease progression over time more easily and cost-effectively than other tests, particularly in clinical trials testing new therapies.
Researchers used the MRIs to predict the ratio of two biomarkers for the diseases - the proteins total tau and beta-amyloid - in the cerebrospinal fluid. Cerebrospinal fluid analyses remain the most accurate method for predicting the disease cause, but requires a more invasive lumbar puncture. “Using this novel method, we obtain a single biologically meaningful value from analyzing MRI data in this manner and then we can derive a probabilistic estimate of the likelihood of Alzheimer’s or FTLD,” said the study’s lead author, Corey McMillan, PhD, of the Perelman School of Medicine and Frontotemporal Degeneration Center at the University of Pennsylvania.
Using the MRI prediction method was 75 percent accurate at identifying the correct diagnosis in both patients with pre-confirmed disease diagnoses and those with biomarker levels confirmed by lumbar punctures, which shows comparable overlap between accuracy of the MRI and lumbar puncture methods. “For those remaining 25 percent of cases that are borderline, a lumbar puncture testing spinal fluid may provide a more accurate estimate of the pathological diagnosis.”
Accurate tests to measure disease progression are very important in neurodegenerative diseases, especially as clinical trials test new therapies to slow or stop the progression or the disease. Biomarkers for neurodegenerative diseases have been steadily improving, with new developments including spinal fluid tests detecting tau and amyloid-beta protein levels and other neuroimaging techniques developed at Penn Medicine, as part of the Alzheimer’s Disease Neuroimaging Initiative. While a spinal fluid test can be used to accurately pinpoint whether disease-specific proteins are present, the test requires a more invasive lumbar puncture making it more difficult to repeat over time. And for studies using other imaging techniques, such as test measuring whole brain volume, reduced sensitivity of the measurement requires more patients to be enrolled in clinical trials for statistical power to be achieved.
“Since this method yields a single biological value, it is possible to use MRI to screen patients for inclusion in clinical trials in a cost-effective manner and to provide an outcome measure that  optimizes power in drug treatment trials,” the authors concluded.

MRI Can Screen Patients for Alzheimer’s Disease or Frontotemporal Lobar Degeneration, Using Penn-designed Model

When trying to determine the root cause of a person’s dementia, using an MRI can effectively and non-invasively screen patients for Alzheimer’s disease or Frontotemporal Lobar Degeneration (FTLD), according to a new study by researchers from the Perelman School of Medicine at the University of Pennsylvania. Using an MRI-based algorithm effectively differentiated cases 75 percent of the time, according to the study, published in the December 26th, 2012, issue of Neurology, the medical journal of the American Academy of Neurology. The non-invasive approach reported in this study can track disease progression over time more easily and cost-effectively than other tests, particularly in clinical trials testing new therapies.

Researchers used the MRIs to predict the ratio of two biomarkers for the diseases - the proteins total tau and beta-amyloid - in the cerebrospinal fluid. Cerebrospinal fluid analyses remain the most accurate method for predicting the disease cause, but requires a more invasive lumbar puncture. “Using this novel method, we obtain a single biologically meaningful value from analyzing MRI data in this manner and then we can derive a probabilistic estimate of the likelihood of Alzheimer’s or FTLD,” said the study’s lead author, Corey McMillan, PhD, of the Perelman School of Medicine and Frontotemporal Degeneration Center at the University of Pennsylvania.

Using the MRI prediction method was 75 percent accurate at identifying the correct diagnosis in both patients with pre-confirmed disease diagnoses and those with biomarker levels confirmed by lumbar punctures, which shows comparable overlap between accuracy of the MRI and lumbar puncture methods. “For those remaining 25 percent of cases that are borderline, a lumbar puncture testing spinal fluid may provide a more accurate estimate of the pathological diagnosis.”

Accurate tests to measure disease progression are very important in neurodegenerative diseases, especially as clinical trials test new therapies to slow or stop the progression or the disease. Biomarkers for neurodegenerative diseases have been steadily improving, with new developments including spinal fluid tests detecting tau and amyloid-beta protein levels and other neuroimaging techniques developed at Penn Medicine, as part of the Alzheimer’s Disease Neuroimaging Initiative. While a spinal fluid test can be used to accurately pinpoint whether disease-specific proteins are present, the test requires a more invasive lumbar puncture making it more difficult to repeat over time. And for studies using other imaging techniques, such as test measuring whole brain volume, reduced sensitivity of the measurement requires more patients to be enrolled in clinical trials for statistical power to be achieved.

“Since this method yields a single biological value, it is possible to use MRI to screen patients for inclusion in clinical trials in a cost-effective manner and to provide an outcome measure that  optimizes power in drug treatment trials,” the authors concluded.

Filed under neurodegenerative diseases alzheimer's disease disease progression diagnosis neuroscience science

  1. crackrock-cat reblogged this from fuckyeahmedicalstuff
  2. jaydensenpai reblogged this from fuckyeahmedicalstuff
  3. chasingrainbowofme reblogged this from fuckyeahmedicalstuff
  4. lemlunay reblogged this from fuckyeahmedicalstuff
  5. sisyphean-signification reblogged this from fuckyeahmedicalstuff
  6. nascent-1 reblogged this from fuckyeahmedicalstuff
  7. karhyol reblogged this from fuckyeahmedicalstuff
  8. overkooled reblogged this from windwaker
  9. windwaker reblogged this from fuckyeahmedicalstuff
  10. bluestarsurgeon reblogged this from fuckyeahmedicalstuff
  11. horseofadifferentcolor reblogged this from fuckyeahmedicalstuff
  12. sadvils reblogged this from polishedspoons
  13. justwannajump reblogged this from fuckyeahmedicalstuff
  14. frolicking-free reblogged this from fuckyeahmedicalstuff
  15. chewinggunsbby reblogged this from sharingneedles
  16. nervvosa reblogged this from sharingneedles
  17. slampigmcqueen reblogged this from sharingneedles
  18. yaoi-cthulhu reblogged this from fuckyeahmedicalstuff
  19. knowaspear reblogged this from fuckyeahmedicalstuff
  20. kazukae reblogged this from fuckyeahmedicalstuff
  21. demonikangel1037 reblogged this from fuckyeahmedicalstuff
  22. danocrow reblogged this from fuckyeahmedicalstuff
  23. disasterolorgy reblogged this from fuckyeahmedicalstuff
  24. mednsciencenshit reblogged this from fuckyeahmedicalstuff
  25. dorasnursing reblogged this from fuckyeahmedicalstuff
  26. gingergonzo reblogged this from fuckyeahmedicalstuff
  27. bambi-slaughter reblogged this from fuckyeahmedicalstuff
  28. aroundthecornerismadness reblogged this from fuckyeahmedicalstuff
free counters